Bonesupport Holding Dividendos y recompras
Dividendo controles de criterios 0/6
Bonesupport Holding no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-0.009%
Rendimiento de la recompra
| Rendimiento total para el accionista | -0.009% |
| Rendimiento futuro de los dividendos | 1.2% |
| Crecimiento de los dividendos | n/a |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Ratio de pago | n/a |
Últimas actualizaciones de dividendos y recompras
No hay actualizaciones
Recent updates
Actualización de narrativa • May 13
BONEX: Infection Study Outcomes And Segment Focus Will Drive Future Upside
Analysts have kept their SEK price target for Bonesupport Holding broadly steady, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this latest narrative update. What's in the News Bonesupport Holding plans an analyst and investor day focused on how its segment based approach is intended to increase penetration and market share for CERAMENT in prioritized indication areas.Artículo de análisis • Apr 25
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Bonesupport Holding AB (publ) ( STO:BONEX ) missed earnings with its latest first-quarter results, disappointing...Actualización de narrativa • Apr 23
BONEX: Clinical Pilot Infection Outcomes Will Support Future Upside Potential
Analysts have raised their price target for Bonesupport Holding by about SEK 10.60 to SEK 377.17, citing updated assumptions that include a slightly higher discount rate, adjusted revenue growth expectations, a revised profit margin outlook, and a lower future P/E multiple. What's in the News Bonesupport Holding announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma.Actualización de narrativa • Apr 07
BONEX: Clinical Pilot Outcomes And 2026 Sales Outlook Will Support Future Upside Potential
Analysts have revised their price target on Bonesupport Holding to SEK 366.6. The update reflects an unchanged fair value along with adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Publication of a US clinical pilot study in OTA International highlighting surgical technique and outcomes for CERAMENT G in trauma cases, providing practical, real world guidance for clinicians considering the product in fracture related infections and osteomyelitis (Key Developments).Actualización de narrativa • Mar 24
BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential
Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.
Nueva narrativa • Mar 12
Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Mar 10
BONEX: Clinical Pilot Results And Strong Guidance Will Support Long-Term Upside Potential
Analysts have trimmed their price target on Bonesupport Holding by SEK 4 to SEK 366.6. This reflects updated assumptions around discount rates, revenue growth and profitability, while keeping future P/E expectations broadly in line with previous views. What's in the News Bonesupport announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma, giving clinicians practical, real world insights into its use in trauma cases.
Nueva narrativa • Feb 25
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Feb 23
BONEX: De Novo Shift Will Support Long Term Upside Potential
Analysts have slightly trimmed their fair value estimate for Bonesupport Holding to SEK370.6, from SEK374.6, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, while keeping the overall thesis broadly intact. What's in the News Bonesupport issued earnings guidance for Q4 2025, with net sales expected at 313 MSEK at constant exchange rates, based on company guidance for that period (company guidance).Artículo de análisis • Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
Key Insights Bonesupport Holding's estimated fair value is kr293 based on 2 Stage Free Cash Flow to Equity Current...Actualización de narrativa • Feb 08
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK374.60 per share. The latest price target update mainly reflects small technical tweaks to the discount rate and future P/E assumptions rather than a shift in the core outlook.Actualización de narrativa • Jan 22
BONEX: De Novo Review Shift Will Support Long Term Upside Potential
Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).Actualización de narrativa • Jan 07
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK391.20, with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This suggests their overall view on the company’s long term potential is essentially unchanged.Actualización de narrativa • Dec 24
BONEX: De Novo Pathway Shift Will Support Strong Future Market Position
Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.Actualización de narrativa • Dec 10
BONEX: Hip Infection Study Success Will Drive Stronger Future Clinical And Market Position
Analysts have modestly raised their price target on Bonesupport Holding to SEK 391.2 per share from SEK 391.2 per share, reflecting largely unchanged long term assumptions on the discount rate, revenue growth, profit margins and future valuation multiples. What's in the News Positive top line data from the CeraHip clinical study show that CERAMENT G enabled successful single stage revision surgery for periprosthetic joint infection of the hip, with no re infections reported over 24 months of follow up (Key Developments).Actualización de narrativa • Nov 25
BONEX: Positive Study Results Will Support Improvements In Hip Infection Outcomes
Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.Artículo de análisis • Nov 22
Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
To the annoyance of some shareholders, Bonesupport Holding AB (publ) ( STO:BONEX ) shares are down a considerable 25...Actualización de narrativa • Nov 07
BONEX: Clinical Study Results Will Drive Long-Term Patient Outcome Improvements
Bonesupport Holding's analyst price target has been updated downward from SEK 401.80 to SEK 391.20, as analysts factor in slightly softer revenue growth forecasts and a higher discount rate. What's in the News Bonesupport announced positive results from a clinical study showing significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection of the hip (Key Developments).Artículo de análisis • Oct 28
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
It's shaping up to be a tough period for Bonesupport Holding AB (publ) ( STO:BONEX ), which a week ago released some...Actualización de narrativa • Oct 24
Positive Clinical Results And US Launch Will Drive Future Success
Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.Artículo de análisis • Aug 25
Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon
Bonesupport Holding AB (publ)'s ( STO:BONEX ) price-to-sales (or "P/S") ratio of 18.3x might make it look like a sell...Artículo de análisis • Jul 23
Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear
Bonesupport Holding AB (publ)'s ( STO:BONEX ) recent soft profit numbers didn't appear to worry shareholders, as the...Artículo de análisis • Jun 28
Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price
Key Insights The projected fair value for Bonesupport Holding is kr508 based on 2 Stage Free Cash Flow to Equity...Artículo de análisis • Apr 28
Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
It's been a good week for Bonesupport Holding AB (publ) ( STO:BONEX ) shareholders, because the company has just...
Nueva narrativa • Mar 19
CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence
CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.Artículo de análisis • Mar 01
kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results
Shareholders of Bonesupport Holding AB (publ) ( STO:BONEX ) will be pleased this week, given that the stock price is up...Artículo de análisis • Oct 31
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders
The market wasn't impressed with the soft earnings from Bonesupport Holding AB (publ) ( STO:BONEX ) recently. Our...Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de BONEX han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de BONEX han aumentado.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de Bonesupport Holding vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (BONEX) | n/a |
| Suelo de mercado 25% (SE) | 1.7% |
| Techo de mercado 25% (SE) | 4.1% |
| Media de la industria (Biotechs) | 2.2% |
| Analista de previsiones (BONEX) (hasta 3 años) | 1.2% |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de BONEX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de BONEX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de BONEX para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que BONEX no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 16:14 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bonesupport Holding AB (publ) está cubierta por 8 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | ABG Sundal Collier |
| Erik Cassel | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |